Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol for mitochondrial diseases
April 21, 2021 07:00 ET | Source: Khondrion Khondrion
Study will examine of sonlicromanol,
candidates in development
for mitochondrial disease
NIJMEGEN, the Netherlands – 21 April 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the first patients have been successfully dosed in its KHENERGYC paediatric Phase II study (NCT04846036) to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children with a genetically confirmed primary mitochondrial disease and suffering from motor symptoms.
Sonlicromanol, Khondrion’s wholly-owned, investigational lead asset, is currently being tested in a Phase IIb study as a potentially disease-modifying treatment for adults with mitochondrial disease. The compound is a
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol .
KhondrionApril 21, 2021 GMT
Study will examine
of sonlicromanol,
candidates in development
for mitochondrial disease
NIJMEGEN, the Netherlands – 21 April 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the first patients have been successfully dosed in its KHENERGYC paediatric Phase II study ( NCT04846036 ) to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children with a genetically confirmed primary mitochondrial disease and suffering from motor symptoms.
ADVERTISEMENT